Switch to Ritonavir-Boosted versus Unboosted Atazanavir plus Raltegravir Dual-Drug Therapy Leads to Similar Efficacy and Safety Outcomes in Clinical Practice.

To assess immunovirological response, safety and pharmacokinetic of NRTI-sparing regimen dual therapy of atazanavir (ATV) and raltegravir (RAL) in maintenance strategy.A retrospective analysis was conducted on a cohort of HIV-infected adults followed in French centers (Dat'AIDS cohort), comparing th...

Бүрэн тодорхойлолт

Номзүйн дэлгэрэнгүй

Үндсэн зохиолчид:	Pierre Gantner, Firouze Bani-Sadr, Rodolphe Garraffo, Pierre-Marie Roger, Michèle Treger, Thomas Jovelin, Pascal Pugliese, David Rey, Dat’AIDS cohort
Формат:	Artigo
Хэл сонгох:	Inglês
Хэвлэсэн:	Public Library of Science (PLoS) 2016-01-01
Цуврал:	PLoS ONE
Онлайн хандалт:	http://europepmc.org/articles/PMC5087881?pdf=render
Шошгууд:	Шошго нэмэх Шошго байхгүй, Энэхүү баримтыг шошголох эхний хүн болох!